Aims | In Vitro | In Vivo |
---|---|---|
Utilise a known DENV mAb to create a vaccine that can neutralise both DENV and ZIKV. | Use RVPs to conduct studies in Raji DC-SIGNR and U937 cells to investigate whether DENV and ZIKV stoichiometry determines the quantitative relationship between neutralisation and ADE. | Create a VLP using the EDE1 region to which C10 mAbs are directed to test protection against ZIKV and DENV challenge in a suitable immunocompetent mouse model. |
Examine the nature of cross-reactive serum using physiologically relevant antibody titres at varying incubation periods. | Explore the multiple hit hypothesis with immune sera to observe the effects of antibodies binding to multiple antigens. Use molecular modelling and reporter GFP expression in RVPs to measure neutralisation. | Investigate whether ADE by convalescent serum aids the trans-placental transfer of ZIKV in mouse models. |